Atrial Fibrillation Management in Outpatient Setting

Initial Assessment and Diagnostic Workup

• The European Society of Cardiology recommends obtaining a 12-lead ECG to confirm the diagnosis of atrial fibrillation and assess for pre-excitation, left ventricular hypertrophy, prior myocardial infarction, and baseline QT interval 4, 5
• The American College of Cardiology suggests ordering transthoracic echocardiography to evaluate left atrial size, left ventricular dimensions, wall thickness, ejection fraction, and exclude valvular disease, pericardial disease, or hypertrophic cardiomyopathy 4, 5, 7
• The European Heart Journal recommends obtaining laboratory tests including complete blood count, serum electrolytes, thyroid function, renal function, hepatic function, and troponin if acute coronary syndrome is suspected 4, 5

Rate Control Strategy

• The European Heart Journal states that beta-blockers are the first-line medication for rate control in patients with preserved left ventricular function, as they effectively control heart rate at rest and during exercise 1, 2, 3
• The American College of Cardiology recommends targeting a heart rate of <110 bpm at rest and during exercise 1, 3

Anticoagulation for Stroke Prevention

• The European Heart Journal recommends calculating the CHA₂DS₂-VASc score immediately to assess stroke risk 1, 3
• The European Society of Cardiology suggests that for a CHA₂DS₂-VASc score ≥2, oral anticoagulation is strongly recommended 1, 2
• The American College of Cardiology recommends using direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, or edoxaban, due to lower risk of intracranial hemorrhage and fewer drug-food interactions 1, 2, 3

Rhythm Control Considerations

• The European Heart Journal recommends considering rhythm control in patients who remain symptomatic despite adequate rate control, or in younger patients with minimal structural heart disease who prefer to maintain sinus rhythm 1, 2, 3
• The American College of Cardiology suggests that if cardioversion is planned and AF duration is >24 hours or unknown, provide at least 3 weeks of therapeutic oral anticoagulation before cardioversion 1, 2

Monitoring and Follow-Up

• The European Heart Journal recommends monitoring PR interval, QRS duration, and QT interval after each dose change of antiarrhythmic drugs 5, 9
• The American College of Cardiology suggests checking heart rate weekly by pulse rate, event recorder, or office ECG tracings 5, 9